文献速递骨质疏松与代谢性骨病

骨质疏松患者使用利塞膦酸胃抵抗剂型与其他口服双膦酸盐的骨折率与经济结局:索赔数据分析

Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
PubMed 文献 · Osteoporos Int · 2021-09-06

该索赔数据分析比较了美国骨质疏松女性使用利塞膦酸胃抵抗剂型(GR)与其他口服双膦酸盐的骨折率和经济结局。GR队列任何部位骨折发生率(IRR 0.83,95%CI 0.70-0.97)和脊柱骨折发生率(IRR 0.71,95%CI 0.54-0.95)更低,住院次数和费用也更少,但2年停药率更高(80.5% vs 74.4%)。

要点

  • GR队列任何骨折IRR 0.83(95%CI 0.70-0.97),脊柱骨折IRR 0.71(95%CI 0.54-0.95)。
  • GR队列2年停药率80.5%,其他口服双膦酸盐队列74.4%。
  • GR队列住院率106.74/1000患者年,其他队列124.20/1000患者年(p<0.05)。

核心结论

  • 处方利塞膦酸GR的患者相比其他口服双膦酸盐骨折发生率更低,可能与其食物同服仍可吸收有关。

研究设计与样本

  • 美国女性骨质疏松索赔数据分析,按首次口服双膦酸盐分为GR队列和其他队列,1:1匹配后观察至少2年,每队列2726例,中位年龄60.0岁。

主要发现

  • GR队列任何部位骨折发生率IRR 0.83(95%CI 0.70-0.97),脊柱骨折IRR 0.71(95%CI 0.54-0.95)。
  • GR队列首次骨折时间延迟,36个月后差异达统计学显著。
  • GR队列住院率106.74/1000患者年 vs 其他队列124.20/1000患者年(p<0.05),人均年住院费用$3,611 vs $4,603(p<0.05)。
  • 2年药物停药率GR队列80.5%,其他队列74.4%。

关键数值与推荐

  • 任何部位骨折发生率IRR 0.83(95%CI 0.70-0.97)。
  • 脊柱骨折发生率IRR 0.71(95%CI 0.54-0.95)。
  • 住院率GR 106.74/1000患者年,其他124.20/1000患者年(p<0.05)。
  • 人均年住院费用GR $3,611,其他$4,603(p<0.05)。
  • 2年停药率GR 80.5%,其他74.4%。

临床怎么用

  • 对于骨质疏松女性,处方便利的利塞膦酸GR剂型可能降低骨折风险和住院负担。
  • 需关注GR剂型2年停药率较高(80.5%),应加强用药 persistence 管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Patients with osteoporosis prescribed risedronate gastro-resistant had a lower incidence of fractures versus those prescribed other oral bisphosphonates. Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its improved efficacy. PURPOSE: Up to half of patients do not follow complex dosing instructions of immediate-release bisphosphonates used for the prevention of osteoporotic fractures, which can result in suboptimal effectiveness. Risedronate gastro-resistant (GR) offers a more convenient dosing option by eliminating the need for fasting. This study compares fracture rates and outcomes between osteoporosis women treated with risedronate GR (GR cohort) versus other oral bisphosphonates (other cohort). METHODS: Claims from women with osteoporosis in the USA were analyzed. Patients were classified into the two cohorts based on the first oral bisphosphonate observed (index date) and matched 1:1 based on patient characteristics. Patients were observed for ≥ 2 years following the index date. Fracture rates, health care resource utilization and costs, and treatment persistence were compared. RESULTS: In total, 2,726 patients were selected in each cohort (median age: 60.0 years). The incidence of fractures was lower in the GR versus the other cohort for any fracture sites (incidence rate ratio, 95% CI: 0.83, 0.70-0.97) and spine fractures (0.71, 0.54-0.95), although the respective rate of medication discontinuation at 2 years was 80.5% and 74.4%. Time to first fracture was delayed for the GR cohort, reaching statistical significance after 36 months. The GR cohort incurred fewer hospitalizations (incidence rate per 1,000 patient-years: GR = 106.74; other = 124.20, p < 0.05) translating into lower hospitalization costs per patient per year (GR = $3,611; other = $4,603, p < 0.05). CONCLUSIONS: Patients prescribed risedronate GR versus other bisphosphonates had a lower incidence of fractures, which may be explained by the fact that the GR formulation is absorbed even when taken with food.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Thomasius F, Palacios S, Alam A, et al. Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. Osteoporos Int. 2021. PMID: 34490504. doi:10.1007/s00198-021-06108-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。